Gilead Gets $900 Million In Sales for Coronavirus Drug and Are AirPod Pro’s Made by Amateurs?
In the third quarter of 2020, Gilead Sciences Inc. brought in a total of $900 million in sales from its COVID-19 drug. The drug has been referred to as both Veklury and Remdesivir.
This data was presented in their latest earnings release, which beat analyst estimates. Since the beginning of 2020, Gilead shares have gained a bit more than 10%. Following the earning release, the stock dropped slightly.
Apple’s AirPod Pro’s are known for their noise cancelling feature, among other stylish things. Many users haven’t been satisfied by the product and have reported “crackling and/or static sounds” as well as other defects. If this sounds like the pair you own, you may be in luck.
Apple has acknowledged AirPod Pro problems and intends to fix it by launching an official “AirPods Pro Service Program” and its main task will be to swap out and replace crackling buds. Apple reported earnings last week and shares fell around 4.5%, while the Nasdaq fell around 4.6%.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.